Investigation of the Cost Impact of Chirality Status of the Most Commonly Consumed Drugs in Turkey

Ahmet Akıcı; Caner Vızdıklar; Şeyhmus Gavaş; Nazım Haspolat; Dieudonne Havyarimana; Selcan Tülü Çolak; Volkan Aydın

Article Details

Investigation of the Cost Impact of Chirality Status of the Most Commonly Consumed Drugs in Turkey

Authors:

Ahmet Akıcı | Caner Vızdıklar | Şeyhmus Gavaş | Nazım Haspolat | Dieudonne Havyarimana | Selcan Tülü Çolak | Volkan Aydın

Publisher:

Mugla Sitki Kocman University

Main Topics:

Klinik Tıp Bilimleri (Diğer)

Journal:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 1, pp.12-20

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001345923

pISSN:

2148-8118

Keywords:

Abstract:

 Chirality is among the factors impacting drug activity in terms of therapeutic or adverse effects. Pure enantiomeric drugs, presumed to offer greater benefits in accordance with this concept, have been recommended for new drug development. We aimed to analyse the chirality status of the commonly consumed drugs in Turkey and assess their cost implications. We evaluated top-selling 200 active substances using nationwide sales data from IQVIA Turkey, identifying chirality status of 173. These were categorized into chiral mixtures, achiral, and pure enantiomers, and their distribution and mean cost per unit CPU values by chirality status were examined. To examine the impact of chiral switching on expenses, CPUs of chiral-switched mixtures and resulting pure enantiomers, were compared. Among 173 compounds, 35.8 were achiral, 22.0 were chiral mixtures and 42.2 were pure enantiomers. Total cost was 2.09b, with pure enantiomers accounting for 46.4 and chiral mixtures 22.0. Mean CPUs for pure enantiomers 2.83.5, achiral drugs 2.32.5, and chiral mixtures 1.70.9 were similar p0.05. For drugs that underwent chiral switching, mean CPU of chiral mixtures 1.40.4 was similar to that of pure enantiomers 1.71.2, p0.05. Half of the chiral pairs that underwent switching had higher CPU for chiral mixture, while the other half had higher CPU for pure enantiomer. We demonstrated that pure enantiomers occupy a significant portion of top-selling drugs in Turkey. The observed cost similarity between commonly used pure enantiomers and chiral mixtures suggests that pure enantiomers may continue to gain preference in the market.

 Chirality is among the factors impacting drug activity in terms of therapeutic or adverse effects. Pure enantiomeric drugs, presumed to offer greater benefits in accordance with this concept, have been recommended for new drug development. We aimed to analyse the chirality status of the commonly consumed drugs in Turkey and assess their cost implications. We evaluated top-selling 200 active substances using nationwide sales data from IQVIA Turkey, identifying chirality status of 173. These were categorized into chiral mixtures, achiral, and pure enantiomers, and their distribution and mean cost per unit CPU values by chirality status were examined. To examine the impact of chiral switching on expenses, CPUs of chiral-switched mixtures and resulting pure enantiomers, were compared. Among 173 compounds, 35.8 were achiral, 22.0 were chiral mixtures and 42.2 were pure enantiomers. Total cost was 2.09b, with pure enantiomers accounting for 46.4 and chiral mixtures 22.0. Mean CPUs for pure enantiomers 2.83.5, achiral drugs 2.32.5, and chiral mixtures 1.70.9 were similar p0.05. For drugs that underwent chiral switching, mean CPU of chiral mixtures 1.40.4 was similar to that of pure enantiomers 1.71.2, p0.05. Half of the chiral pairs that underwent switching had higher CPU for chiral mixture, while the other half had higher CPU for pure enantiomer. We demonstrated that pure enantiomers occupy a significant portion of top-selling drugs in Turkey. The observed cost similarity between commonly used pure enantiomers and chiral mixtures suggests that pure enantiomers may continue to gain preference in the market.

 Chirality is among the factors impacting drug activity in terms of therapeutic or adverse effects. Pure enantiomeric drugs, presumed to offer greater benefits in accordance with this concept, have been recommended for new drug development. We aimed to analyse the chirality status of the commonly consumed drugs in Turkey and assess their cost implications. We evaluated top-selling 200 active substances using nationwide sales data from IQVIA Turkey, identifying chirality status of 173. These were categorized into chiral mixtures, achiral, and pure enantiomers, and their distribution and mean cost per unit CPU values by chirality status were examined. To examine the impact of chiral switching on expenses, CPUs of chiral-switched mixtures and resulting pure enantiomers, were compared. Among 173 compounds, 35.8 were achiral, 22.0 were chiral mixtures and 42.2 were pure enantiomers. Total cost was 2.09b, with pure enantiomers accounting for 46.4 and chiral mixtures 22.0. Mean CPUs for pure enantiomers 2.83.5, achiral drugs 2.32.5, and chiral mixtures 1.70.9 were similar p0.05. For drugs that underwent chiral switching, mean CPU of chiral mixtures 1.40.4 was similar to that of pure enantiomers 1.71.2, p0.05. Half of the chiral pairs that underwent switching had higher CPU for chiral mixture, while the other half had higher CPU for pure enantiomer. We demonstrated that pure enantiomers occupy a significant portion of top-selling drugs in Turkey. The observed cost similarity between commonly used pure enantiomers and chiral mixtures suggests that pure enantiomers may continue to gain preference in the market.

 Kiralite, terapötik veya advers etkiler yönünden ilaç aktivitesini etkileyen faktörler arasındadır. Yeni ilaç geliştirilmesinde, bu kavram doğrultusunda daha fazla fayda sağladığı düşünülen saf enantiyomer ilaçlar tavsiye edilmiştir. Bu çalışmada Türkiyede sık tüketilen ilaçların kiralite durumları ve bunların maliyete yansımaları incelendi. Çalışmada IQVIA Türkiye biriminden alınan satış verileri kullanılarak ülke genelinde en fazla satılan ilk 200 etkin madde değerlendirildi ve 173ünün kiralite durumu tespit edildi. Bu ilaçlar kiral karışım, akiral ve saf enantiyomer olmak üzere üç gruba ayrılmalarının ardından kiralite durumlarına göre dağılımları ve ortalama kutu başına düşen KBD maliyetleri incelendi. Kiral dönüşümün maliyete yansımasını incelemek amacıyla dönüşüme uğrayan kiral karışımlarla bu işlem sonucunda meydana gelen saf enantiyomerler bu parametreler yönünden karşılaştırıldı. Kiralite durumu incelenen 173 etkin maddenin 35.8i akiral, 22.0ı kiral karışım ve 42.2si saf enantiyomerdi. Toplam maliyet 2.09 milyar  iken, maliyetin 46.4ünü saf enantiyomerler, 22.0ını ise kiral karışımlar oluşturmaktaydı. KBD maliyet ortalamaları bakımından saf enantiyomerler 2.83.5 , akiral ilaçlar 2.32.5  ve kiral karışımlar 1.70.9  istatistiksel olarak benzerdi p0.05. Kiral dönüşüme uğrayan ilaçlarda kiral karışımların ortalama KBD maliyeti 1.40.4 , saf enantiyomerlerinki 1.71.2  ile benzerdi p0.05. Kiral dönüşüme uğrayan ilaçların yarısında KBD maliyeti, kiral karışımda daha yüksekken diğer yarısında ise saf enantiyomerde daha yüksekti. Bu çalışmada Türkiyede en çok satan ilaçlar arasında saf enantiyomerlerin önemli ölçüde yer tuttuğu ortaya konuldu. Sık kullanılan saf enantiyomer ve kiral karışımların maliyet yönünden benzer olması, saf enantiyomerlerin piyasada tercih edilme durumunun devam edebileceğini düşündürmektedir.

Article Details

Investigation of the Cost Impact of Chirality Status of the Most Commonly Consumed Drugs in Turkey

Authors:

Ahmet Akıcı | Caner Vızdıklar | Şeyhmus Gavaş | Nazım Haspolat | Dieudonne Havyarimana | Selcan Tülü Çolak | Volkan Aydın

Publisher:

Mugla Sitki Kocman University

Main Topics:

Klinik Tıp Bilimleri (Diğer)

Journal:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 1, pp.12-20

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001345923

pISSN:

2148-8118

Drug Expenditure

Chirality

Chiral Switch

Chiral Mixture

Pure Enantiomerİlaç Harcamaları

Kiralite

Kiral Dönüşüm Kiral Karışım

Saf Enantiyomer

Issues

Article Details

Authors: Ahmet Akıcı | Caner Vızdıklar | Şeyhmus Gavaş | Nazım Haspolat | Dieudonne Havyarimana | Selcan Tülü Çolak | Volkan Aydın

Publisher: Mugla Sitki Kocman University

Main Topics: Klinik Tıp Bilimleri (Diğer)

Journal: Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 1, pp.12-20

Document Type: Article

Publication Date: 4/2025

Document Language: English

Document ID (Org No.): 2001345923

pISSN: 2148-8118

Issues

Authors:

Ahmet Akıcı | Caner Vızdıklar | Şeyhmus Gavaş | Nazım Haspolat | Dieudonne Havyarimana | Selcan Tülü Çolak | Volkan Aydın

Publisher:

Mugla Sitki Kocman University

Main Topics:

Klinik Tıp Bilimleri (Diğer)

Journal:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.12 Issue 1, pp.12-20

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001345923

pISSN:

2148-8118